Meta‐analysis of the association between sodium‐glucose co‐transporter‐2 inhibitors and risk of skin cancer among patients with type 2 diabetes by Tang, Huilin et al.
tang huilin (Orcid ID: 0000-0002-5814-6657) Song Yiqing (Orcid ID: 0000-0002-2097-7332) Han Jiali (Orcid ID: 0000-0002-8309-7092) 
Meta-analysis of the association between sodium–glucose cotransporter 2 
inhibitors and risk of skin cancer among patients with type 2 diabetes  
Short title: SGLT2 inhibitors and Skin Cancer 
Huilin Tang MSc1, Keming Yang MD1, Yiqing Song MD, ScD1, Jiali Han PhD1,2 
1 Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana 
University, Indianapolis, Indiana, USA  
2Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana，USA 
Corresponding author: 
Jiali Han, PhD 
Department of Epidemiology,  
Richard M. Fairbanks School of Public Health, Indiana University,  
1050 Wishard Blvd, Indianapolis, Indiana, 46202, USA 
Phone: 317-278-0370; Fax: 317-274-3433 
Email: jialhan@iu.edu 
Brief Report 
Word count: 1464 
Number of tables/figures: 1/1 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Tang, H., Yang, K., Song, Y., & Han, J. (2018). Meta-analysis of the association between sodium–glucose 
cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes. Diabetes, Obesity and 
Metabolism, 0(ja). https://doi.org/10.1111/dom.13474
   
ABSTRACT 
A slight increase in melanoma risk was observed among sodium-glucose cotransporter 2 
(SGLT2) inhibitor users in the regular reports. However, the association remains 
uncertain. To address this issue, we performed a systematic search of electronic 
databases up to May 2, 2018 and a meta-analysis of 21 randomized controlled trials 
(RCTs) involving 20,816 patients. We did not find a significant increase in risk of 
melanoma among SGLT2 inhibitor users (Peto odds ratio [OR], 2.17; 95% confidence 
interval [CI], 0.80 to 5.89; I2, 0%). Similar results were observed in the subgroup 
analyses according to type of SGLT2 inhibitor, type of control, ages of patients, 
race/ethnicity, and trial durations. For non-melanoma skin cancer risk, no significant 
difference was observed when all trials were combined (Peto OR, 0.70; 95% CI, 0.47 to 
1.07; I2, 0%) while a significantly decreased risk was observed among trials with duration 
< 52 weeks (Peto OR, 0.12; 95% CI, 0.02 to 0.59; I2, 0%). No evidence of publication 
was detected in the analyses. Current evidence from RCTs did not support a significantly 
increased risk of skin cancer associated with SGLT2 inhibitors. 
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1 INTRODUCTION 
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antidiabetic 
drugs for the treatment of type 2 diabetes (T2D).1 They lower blood glucose by inhibiting 
the reabsorption of glucose in the kidney. Given their additional benefits to the 
cardiovascular and renal systems,2-5 more and more patients will be prescribed this class 
of medication. However, some evidence has indicated that SGLT2 inhibitors may lead to 
serious adverse events (e.g., diabetic ketoacidosis and below-knee lower extremity 
amputation).6, 7 Furthermore, a slightly elevated risk of melanoma associated with 
empagliflozin use raises regulatory concerns.8, 9 Given the rarity of melanoma cases in 
most randomized controlled trials (RCTs), such safety issues are difficult to be 
addressed based on any individual short-term trial. Therefore, we conducted this 
meta-analysis of RCTs to comprehensively synthesize the evidence and maximize 
statistical power to detect any association between SGLT2 inhibitors and risk of skin 
cancer, including melanoma and non-melanoma skin cancer (NMSC) among patients 
with T2D. 
 
2 METHODS  
2.1 Search strategy and study selection 
PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and 
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ClinicalTrials.gov were searched from inception to May 2, 2018 using relevant search 
terms without language restrictions (Table S1). The reference lists of included studies, 
review articles, and meta-analyses were checked to find additional eligible trials. 
We included eligible trials that fulfilled the following criteria: 1) published and 
unpublished RCTs; 2) adults patients with T2D; 3) comparison of SGLT2 inhibitors with 
placebo or other antidiabetic drugs; 4) trials with follow-up for at least 12 weeks; 5) 
reported the outcomes of melanoma and NMSC (basal cell carcinoma and squamous 
cell carcinoma).  
2.2 Data extraction and risk of bias assessment 
Two reviewers independently selected the potential trials, extracted data, and assessed 
the risk of bias of included trials. Any disagreements were resolved by consensus. We 
extracted the baseline demographic data, type of SGLT2 inhibitor, type of control, 
background therapy, trial duration, and outcomes of interest. The data from the trial with 
longest follow-up period were used in case of various follow-up periods reported. For a 
three-arm trial comparing A+B vs. A vs. B, only two arms (A vs. B) were included in the 
meta-analysis. If skin cancer events were not reported in publication, these data were 
extracted from Clinicaltrials.gov website (www.clinicaltrials.gov). The risk of bias for each 
trial was assessed according to the Cochrane Collaboration tool for assessing risk of 
bias.10  
2.3 Statistical analysis 
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Due to rare incidence of skin cancer events, we used Peto odds ratio (OR) with 95% 
confidence interval (CI) to pool the data.11 A I² statistic was performed to test 
between-study heterogeneity, with a I2 value of 25% - 50%, 50% - 75%, and > 75% 
corresponding to low, moderate, and high, respectively while a value of I2 < 25% 
represented no significant heterogenity.12 To explore the source of heterogeneity, 
subgroup analyses were carried out based on type of SGLT2 inhibitor (empagliflozin 
versus canagliflozin versus dapagliflozin versus ertugliflozin versus ipragliflozin), type of 
control (placebo versus other active antidiabetic drugs), race/ethnicity (white versus 
Asian), mean or median age of patients (< 60 years versus ≥ 60 years), and trial 
duration(< 52 weeks versus ≥ 52 weeks). To test interactions by these prespecified 
factors, p values for interactions were provided based on Cochran’s Q test for assessing 
differences between the subgroups stratified by each factor, respectively. Further, 
meta-regression including each stratified factor as an independent variable (on a 
dichotomous scale) was also performed to investigate if the heterogeneity changed 
significantly between the subgroups stratified by that factor mentioned above.13 Potential 
publication bias was assessed using both funnel plot and egger’s test. All statistical 
analyses were performed with STATA version 14 (College station, TX). A p value < 0.05 
was considered as statistically significant. 
 
3 RESULTS 
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Among the 3,628 citations retrieved from the above-mentioned electronic databases, 21 
eligible RCTs involving 20,816 patients (median: 690; range: 332 to 7,020 individuals) 
were included in this meta-analysis (Figure S1). The characteristics and risk of bias of 
the studies included were presented in Table S2 and Figure S2 respectively. The 
incidence of skin cancers was reported in only three articles and the others were 
extracted from www.clinicaltrials.gov. 
   There were 15 incident cases of melanoma in the SGLT2 inhibitor group and 3 in the 
control group during follow-up (median: 52 weeks; range: 12 to 160 weeks). The event 
rate in the SGLT2 inhibitor group (0.1%) was higher than in the control group (0.04%), 
yielding a Peto OR of 2.17 (95% CI, 0.80 to 5.89) (Figure 1). The subgroup analyses 
according to type of SGLT2 inhibitor, type of control, mean or median ages of patients, 
race/ethnicity, and trial durations did not identify any significant associations (Table 1).  
   In terms of NMSC risk, no significant association with SGLT2 inhibitors was observed 
when all trials were combined (Peto OR, 0.70; 95% CI, 0.47 to 1.07), with event rates of 
0.4% in the SGLT2 inhibitor group and 0.6% in the control group (Figure 1). When 
exploring the source of heterogeneity, the risk did not differ by the type of SGLT2 
inhibitor, type of control, mean or median ages of patients (Table 1). However, a 
significantly decreased risk of NMSC associated with SGLT2 inhibitors was observed 
among trials with duration < 52 weeks (Peto OR, 0.12; 95% CI, 0.02 to 0.59), but not 
among those ≥ 52 weeks (Peto OR, 0.80; 95% CI, 0.52 to 1.23) (p for interaction < 0.05) 
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(Table 1).  
   We observed zero, low, and moderate degree of between-study heterogeneity in the 
analyses, with I² ranging from 0% to 56.4% (Table 1). There was no evidence of 
publication bias based on Egger’s test (p = 0.83 for melanoma, and p = 0.54 for NMSC) 
and funnel plot (Figure S3). 
 
4 DISCUSSION 
The present meta-analysis showed that SGLT2 inhibitors were not significantly 
associated with increased risk of melanoma among the patients with T2D. However, we 
cannot rule out the potential for harm. A non-significant decrease in risk of NMSC 
associated with SGLT2 inhibitors was observed, while a significantly decreased risk was 
detected among trials with duration < 52 weeks. There was zero, low, and moderate 
heterogeneity in the meta-analyses. No evidence of potential publication bias was 
observed. 
   Evidence drawn from available RCTs did not suggest a significantly increased risk of 
melanoma associated with SGLT2 inhibitors (mainly empagliflozin), which was in line 
with the European Medicines Agency Assessment Report 8 as well as a pooled analysis 
of 15 trials (four melanoma cases with 10 mg empagliflozin versus two cases with 
placebo).14 Of note, a slightly low incidence of melanoma was observed in the 
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dapagliflozin group (2/2,691) versus in the control group (1/1,936) in our meta-analysis. 
Given unknown biological mechanisms linking SGLT2 inhibition to melanocytic 
carcinogenesis, it is difficult to determine whether the possibly high melanoma risk is 
attributable to empagliflozin use or is simply the result of chance.9 Furthermore, the 
opposite trend was observed for risk of NMSC, indicating that SGLT2 inhibitors may not 
be photosensitizers that increase melanoma risk through phototoxicity. We observed a 
significantly decreased risk of NMSC in the trials with follow-up < 52 weeks but not 
among those with duration ≥ 52 weeks, which might be driven by small number of events 
(1/1913 in SGLT2 inhibitor group versus 6/661 in control group) or possibly due to an 
imbalance in frequency of pre-existing NMSC cases between groups at baseline. 
Therefore, based on current evidence, we were unable to rule out the potential risk of 
melanoma associated with SGLT2 inhibitors, and determine whether a beneficial role of 
SGLT2 inhibitors against NMSC may exist. Ongoing long-term post-marketing 
surveillance is needed to keep monitoring the risk of melanoma and NMSC among 
patients taking SGLT2 inhibitors.  
   We acknowledged that our study had several limitations. First, our estimates may be 
subject to reporting bias because skin cancers were not specified end points in these 
trials which would result in less reports of skin cancers. In addition, only trials reporting 
the outcomes of skin cancer were considered in this meta-analysis. Second, our results 
should be interpreted with caution because of the small number of skin cancer cases and 
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short term of follow-up of included trials (median: 52 weeks). Our findings, especially in 
subgroup analyses, need to be further assessed by future long-term studies. 
Noteworthily, no prospective observational study has examined the association of 
SGLT2 inhibitors and risk of skin cancer yet. Therefore, we could not conduct the 
meta-analysis based on observational data.  
   In conclusion, current evidence from randomized trials did not find a significantly 
increased risk of skin cancer among patients taking SGLT2 inhibitors. However, the 
potential melanoma risk by SGLT2 inhibitors cannot be ruled out and should be further 
monitored in future large prospective observational studies and post-marketing 
surveillance.  
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Table 1. Subgroup and univariable meta-regression analyses of the association between SGLT2 inhibitors and risk of 
melanoma and non-melanoma skin cancer in patients with type 2 diabetes. 
Subgroup 
analyses 
 
No. of 
trials 
No. of 
patients 
(S/C) 
 
Melanoma Non-melanoma skin cancer 
No. of 
events 
(S/C) 
Peto odds ratio 
(95% CI) 
 
Het 
(I2, %
)  
p- 
value
† 
p- 
value‡ 
No. of 
events 
(S/C) 
Peto odds ratio 
(95% CI) 
 
Het 
(I2, %
)  
p- 
value
† 
p- 
value‡ 
Subgroup by type of SGLT2 inhibitor   
Empagliflozin 11 9172/4964 12/2 2.64 (0.88, 7.93) 0 
0.20 0.45 50/35 0.75  (0.48, 1.18) 0 
0.86 0.68 
Dapagliflozin 7 2691/1936 2/1 0.38  (0.02, 7.00) 42.3 4/8 
0.44 
(0.14, 1.38) 12.7 
Canagliflozin 1 477/237 0/0 NA NA 1/0 4.47  (0.07, 286.85) NA 
Ertugliflozin 1 313/154 1/0 4.45  (0.07, 287.44) 
NA 1/1 0.46  (0.02, 8.84) NA 
Ipragliflozin 1 291/73 0/0 NA NA 0/0 NA NA 
Subgroup by type of control   
Placebo 17 11222/5686 13/3 1.80  (0.62, 5.25) 0 
0.29 0.34 52/37 0.74  (0.47, 1.15) 0.2 
0.55 0.58 
Other active 
drugs 5 2170/1678 2/0 
7.55  
(0.47, 120.75) NA 4/7 
0.51  
(0.15, 1.69) 0 
Subgroup by mean or median age of patients   
< 60 years 15 5971/3079 6/1 2.42  (0.46, 12.74) 2.4 
1.0 0.87 9/14 0.43  (0.18, 1.01) 0 
0.16 0.18 
≥ 60 years 6 6973/4285 9/2 2.04  (0.59, 7.12) 0 47/30 
0.82  
(0.51, 1.32) 0 
Subgroup by race/ethnicity   
White 16 11132/6305 15/3 2.17  (0.80, 5.89) 0 
NA NA 55/43 0.71  (0.47, 1.08) 0 
0.75 0.79 
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Asian 5 1812/1059 0/0 NA NA 1/1 0.46  (0.02, 8.80) 56.4 
Subgroup by trial duration   
< 52 weeks 5 1913/661 0/0 NA NA NA NA 1/6 0.12  (0.02, 0.59) 0 
0.01 0.03 
≥ 52 weeks 16 11031/6703 15/3 2.17  (0.80, 5.89) 0 55/38 
0.80  
(0.52, 1.23) 0 
†p-value for potential effect modification by each stratified factor on the pooled effect size estimate based on 
meta-regression models. 
‡p-value for interactions assessed with Cochran’s Q-test. 
Abbreviations: Het, heterogeneity; SGLT2 inhibitor, sodium-glucose co-transporter 2 inhibitor; CI, confidence interval; S/C, 
SGLT2 inhibitors group/control group; NA, not applicable. 
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Figure Legends:   
Figure 1. Meta-analysis of the association between SGLT2 inhibitors and risk of 
melanoma and non-melanoma skin cancer in patients with type 2 diabetes. 
This article is protected by copyright. All rights reserved.
   
Figure 1  
.
.
Melanoma
Ferrannini et al  2010
Bailey et al 2013
Barnett et al 2014
Haring et al 2014
Ridderstrale et al 2014
Zinman et al 2015
Grunberger et al 2018
Nauck et al 2011
Haring et al 2013
Roden et al 2013
Jabbour et al 2014
Kashiwagi 2014
Kovacs et al 2014
Leiter et al 2014
Bode et al 2015
Cefalu et al 2015
Lewin et al 2015 and DeFronzo et al 2015
NCT01649297 2015
Yang et al 2015
Softeland et al 2016
Subtotal  (I-squared = 0.0%, p = 0.620)
Non-melanoma skin cancer
Nauck et al 2011
Bailey et al 2013
Barnett et al 2014
Haring et al 2014
Jabbour et al 2014
Kovacs et al 2014
Leiter et al 2014
Ridderstrale et al 2014
Bode et al 2015
Cefalu et al 2015
Lewin et al 2015 and DeFronzo et al 2015
NCT01649297 2015
Yang et al 2015
Zinman et al 2015
Softeland et al 2016
Grunberger et al 2018
Ferrannini et al  2010
Haring et al 2013
Roden et al 2013
Kashiwagi 2014
Subtotal  (I-squared = 0.0%, p = 0.613)
Study
0.07 (0.00, 3.29)
3.80 (0.04, 349.25)
5.82 (0.11, 304.22)
4.40 (0.07, 288.91)
7.55 (0.47, 120.75)
1.82 (0.49, 6.78)
4.45 (0.07, 287.44)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
2.17 (0.80, 5.89)
0.14 (0.00, 6.85)
3.80 (0.04, 349.25)
0.10 (0.01, 1.62)
4.40 (0.07, 288.91)
0.13 (0.02, 0.96)
4.46 (0.07, 287.01)
1.95 (0.20, 18.83)
0.62 (0.15, 2.48)
4.47 (0.07, 286.85)
1.00 (0.06, 16.08)
0.45 (0.02, 8.73)
3.07 (0.01, 1660.95)
0.05 (0.00, 3.06)
0.82 (0.49, 1.35)
0.05 (0.00, 3.15)
0.46 (0.02, 8.84)
(Excluded)
(Excluded)
(Excluded)
(Excluded)
0.70 (0.47, 1.07)
OR (95% CI)
1/410
1/409
1/419
1/430
2/765
8/4687
1/313
0/406
0/441
0/448
0/225
0/291
0/333
0/482
0/477
0/460
0/551
0/876
0/299
0/222
15/12944
0/406
1/409
0/419
1/430
0/225
1/333
2/482
3/765
1/477
1/460
1/551
1/876
0/299
43/4687
0/222
1/313
0/410
0/441
0/448
0/291
56/12944
inhibitors
Events, SGLT2
1/75
0/137
0/319
0/207
0/780
2/2333
0/154
0/408
0/225
0/451
0/226
0/73
0/165
0/483
0/237
0/462
0/267
0/107
0/145
0/110
3/7364
1/408
0/137
2/319
0/207
4/226
0/165
1/483
5/780
0/237
1/462
1/267
0/107
1/145
26/2333
1/110
1/154
0/75
0/225
0/451
0/73
44/7364
Control
Events,
6.78
4.88
6.37
5.70
12.98
57.55
5.74
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
100.00
1.12
0.84
2.19
0.98
4.43
0.99
3.34
8.89
0.99
2.23
1.96
0.43
0.98
67.68
0.99
1.97
0.00
0.00
0.00
0.00
100.00
Weight
%
  
1.1 10
 
This article is protected by copyright. All rights reserved.
